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Abstract
Background: Although the risk factors for positive follow-up blood cultures (FUBCs) in gram-negative bacteremia
(GNB) have not been investigated extensively, FUBC has been routinely carried out in many acute care hospitals.
We attempted to identify the risk factors and develop a predictive scoring model for positive FUBC in GNB cases.
Methods: All adults with GNB in a tertiary care hospital were retrospectively identified during a 2-year period, and
GNB cases were assigned to eradicable and non-eradicable groups based on whether removal of the source of
infection was possible. We performed multivariate logistic analyses to identify risk factors for positive FUBC and built
predictive scoring models accordingly.
Results: Out of 1473 GNB cases, FUBCs were carried out in 1268 cases, and the results were positive in 122 cases. In case
of eradicable source of infection, we assigned points according to the coefficients from the multivariate logistic regression
analysis: Extended spectrum beta-lactamase-producing microorganism (+ 1 point), catheter-related bloodstream infection
(+ 1), unfavorable treatment response (+ 1), quick sequential organ failure assessment score of 2 points or more (+ 1),
administration of effective antibiotics (− 1), and adequate source control (− 2). In case of non-eradicable source of
infection, the assigned points were end-stage renal disease on hemodialysis (+ 1), unfavorable treatment response (+ 1),
and the administration of effective antibiotics (− 2). The areas under the curves were 0.861 (95% confidence interval [95CI]
0.806–0.916) and 0.792 (95CI, 0.724–0.861), respectively. When we applied a cut-off of 0, the specificities and negative
predictive values (NPVs) in the eradicable and non-eradicable sources of infection groups were 95.6/92.6% and 95.5/
95.0%, respectively.
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Conclusions: FUBC is commonly carried out in GNB cases, but the rate of positive results is less than 10%. In our simple
predictive scoring model, zero scores—which were easily achieved following the administration of effective antibiotics
and/or adequate source control in both groups—had high NPVs. We expect that the model reported herein will reduce
the necessity for FUBCs in GNB cases.
Keywords: Gram-negative bacteremia, Follow-up blood culture, Persistent bacteremia, Risk factor, Predictive scoring
model
Background
Although the positive rate of detection from follow-up
blood cultures (FUBCs) in gram-negative bacteremia
(GNB) is relatively low (5.8–10.9%) [1–3], and the risk fac-
tors for persistent GNB have not been investigated exten-
sively, FUBCs have been routinely conducted in cases of
GNB in many acute care hospitals [1–4]. Unnecessary
routine blood cultures are invasive, and false positives due
to contamination increase medical costs and time spent in
hospitals [2, 5, 6]. The authors of a previous study identi-
fied the risk factors for persistent bacteremia, and fever
was found to be the only risk factor associated with GNB
[1]. Owing to the rarity of persistent GNB, the previous
study had limitations, including an insufficient number of
persistent GNB cases.
Recently, several studies have reported that a shorter course
of antibiotics in uncomplicated GNB (hemodynamically
stable patients who have received effective antibiotics and ad-
equate source control) [7, 8] does not produce an inferior
prognosis compared to a longer course. Further, a recent ran-
domized control study showed that a 7-day course of anti-
biotic therapy in uncomplicated GNB was not inferior to a
14-day course. Thus, FUBCs may not be necessary for the
management of uncomplicated GNB, since it can be ad-
equately treated by a short course of antibiotics [8].
Therefore, we attempted to identify the risk factors for
a positive FUBC result in GNB and developed a predict-




We retrospectively reviewed all gram-negative episodes
of bacteremia in a tertiary care university-affiliated 1300-
bed hospital in South Korea from December 1, 2015 to
December 1, 2017. Patients under 18 years of age, those
who died within 2 days, and patients with concomitant
gram-positive bacteremia or fungemia were excluded
from the study (Fig. 1). New episodes of bacteremia
identified by FUBC (different species were identified by
the FUBC than those identified in the initial blood cul-
ture) were also excluded when we compared the FUBC-
positive and -negative groups. The study was approved
by the institutional review board of Seoul National Uni-
versity Bundang Hospital.
Variables and groups
The variables were as follows: comorbidities, primary
sources of infection, antibiotic status at the time of
FUBC, identified microorganisms, susceptibility to anti-
biotics, fever, complete blood count, levels of C-reactive
protein (CRP), quick sequential organ failure assessment
(qSOFA) score, sequential organ failure assessment
(SOFA) score, inotropic requirement, and source control
status.
Patients who were subjected to FUBC 2–7 days after
the initial blood culture, were assigned to the FUBC
group, whereas patients who were not subjected to
FUBC were assigned to the No-FUBC group. Cases were
assigned to the FUBC-positive group if the same species
of microorganism as the initial bacteremia was identified
in at least one pair of FUBCs, and it was defined as per-
sistent bacteremia. Cases in which bacteremia had been
eliminated were assigned to the FUBC-negative group.
GNB was classified into eradicable and non-eradicable
sources of infection according to the possibility of re-
moval of the primary source of infection [9–11]; for ex-
ample, removal of a central venous catheter or other
endovascular devices; drainage of a dilated bile duct or
hydronephrosis; surgical debridement of the skin, soft
tissue infection, or osteomyelitis; drainage or removal of
an intra-abdominal abscess; and drainage of empyema or
a lung abscess.
An unfavorable treatment response was defined as the
presence of at least two of the following variables: fever,
aggravated leukocytosis, and no decrease in the level of
CRP on the day that the FUBC was performed. Suscep-
tible antibiotics were deemed to have been administered
effectively when they were administered at least 1 calen-
dar day before the FUBC according to the results of the
antibiotics sensitivity test conducted in compliance with
the Clinical and Laboratory Standards Institute (CLSI)
guidelines. Adequate source control was defined as con-
trol of an eradicable source of infection at least 1 calen-
dar day before the FUBC was performed [3, 10].
We compared the differences in clinical characteristics
between the FUBC and the no-FUBC groups to assess
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selection bias. Subsequently, we divided the FUBC group
into eradicable and non-eradicable sources of infection
and performed multivariate logistic regression analyses
to identify the independent risk factors for a positive
FUBC. If species different from the one causing the ini-
tial bacteremia were identified in the FUBC, it was con-
sidered a new bacteremia and excluded from the
analysis. We built a predictive scoring model by assign-
ing scores according to the beta-coefficient of the logis-
tic regression analyses and verified it using receiver
operating characteristic curve (ROC) analysis.
Statistical analyses
The statistical analyses were performed using IBM
SPSS version 25.0. Fisher’s exact and Chi-square tests
were used to analyze categorical variables, and stu-
dent’s t-tests were used for continuous variables.
Multivariate logistic regression analyses were per-
formed using variables with p-values of less than 0.1
in the univariate analyses. A p-value of less than 0.05
was considered statistically significant in the multi-
variate analyses.
Results
Overall, 1481 GNB cases were identified during the study
period. Of these, FUBCs were performed in 1276 cases
(86.2%), and 122 produced positive results (9.6%) (Fig. 1).
There were no cases of suspected contamination, and a
new bacteremia was identified in eight cases of FUBC
(Supplementary Table 1). Comparisons between the
FUBC group and the no-FUBC group are shown in
Table 1. Variables such as hematologic malignancy, the
presence of an intravascular device, and the presence of
extended spectrum beta lactamase (ESBL)-producing mi-
croorganisms were significantly higher in the FUBC
group. There was no significant difference in the incidence
of in-hospital mortality between the two groups.
Positive and negative clinical characteristics in the
FUBC groups are compared in Table 2, according to the
eradicability of the infection source, and the identified in-
dependent risk factors are listed in Table 3. In cases where
the source of infection was eradicable, the independent
risk factors were as follows: the presence of ESBL-
producing microorganisms, catheter-related bloodstream
infection, unfavorable treatment responses, a qSOFA
score of at least 2 points, the administration of effective
Fig. 1 Flow chart of the study. Inclusion and exclusion criteria for the study population. FUBC: follow-up blood culture
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Table 1 Comparisons of clinical characteristics of gram-negative bacteraemia between the follow-up blood culture (FUBC) and no-
FUBC groups
FUBC-drawn (n = 1276) No FUBC-drawn (n = 205) p-value
Age, years (± SD) 68.85 (± 14.27) 69.2 (± 14.13) 0.744
Sex (M) 628 (49.2%) 117 (57.1%) 0.042*
Body weight (kg) 59.90 (± 11.56) 59.24 (± 12.62) 0.533
Comorbidity
DM 404 (31.7%) 70 (34.1%) 0.519
Liver cirrhosis 95 (7.4%) 17 (8.3%) 0.776
ESRD on HD 2 (1.0%) 35 (2.7%) 0.154
ESRD on PD 6 (0.5%) 0 (0.0%) 1.000
Rheumatic disease 18 (1.4%) 1 (0.5%) 0.500
Haematologic malignancy 136 (10.7%) 7 (3.4%) 0.001*
Solid malignancy 361 (28.4%) 60 (29.4%) 0.802
Solid organ transplantation 34 (2.7%) 5 (2.4%) 1.000
Bone marrow transplantation 28 (2.2%) 1 (0.5%) 0.167
Intravascular device 308 (24.1%) 19 (9.3%) 0.000*
Neutropenia 127 (10.0%) 6 (2.9%) 0.002*
High-dose steroid 24 (1.9%) 1 (0.5%) 0.239
Microorganism
Escherichia coli 722 (56.6%) 113 (55.1%) 0.705
Klebsiella pneumoniae 250 (19.6%) 45 (22.0%) 0.451
Pseudomonas aeruginosa 62 (4.9%) 7 (3.4%) 0.384
AmpC-encoded Enterobacteriaceaea 100 (7.8%) 21 (10.2%) 0.237
Acinetobacter baumannii 24 (1.9%) 1 (0.5%) 0.239
ESBL-producing 313 (24.5%) 32 (15.6%) 0.006*
Other gram-negative 110 (8.6%) 17 (8.3%) 0.895
PBSI 50 (3.9%) 8 (3.9%) 1.000
Hospital onset 328 (25.7%) 53 (25.9%) 1.000
Site of infection
Urinary genital tract 502 (39.3%) 71 (34.6%) 0.217
Liver abscess 56 (4.4%) 7 (3.4%) 0.583
Biliary 303 (23.7%) 86 (42.0%) 0.000*
Intra-abdominal 135 (10.6%) 18 (8.8%) 0.462
Respiratory 56 (4.4%) 5 (2.4%) 0.255
SSTI 13 (1.0%) 1 (0.5%) 0.707
Catheter-related 40 (3.1%) 2 (1.0%) 0.109
Bone and joint infection 12 (0.9%) 1 (0.5%) 1.000
Cardiovascular 3 (0.2%) 0 (0.0%) 1.000
CNS infection 3 (0.2%) 0 (0.0%) 1.000
Primary bacteraemia 143 (11.2%) 10 (4.9%) 0.006*
In-hospital mortality 87 (6.8%) 18 (8.8%) 0.379
SD Standard deviation, M Male, DM Diabetes mellitus, ESRD End-stage renal disease, HD Haemodialysis, PD Peritoneal dialysis, ESBL Extended-spectrum beta-
lactamase, PBSI Polymicrobial bloodstream infection, SSTI Skin and soft tissue infection, CNS Central nervous system
aAmpC-encoded Enterobacteriaceae includes Serratia marcescens, Providencia stuartii, Proteus vulgaris, Citrobacter spp., Enterobacter spp., and Morganella morganii
*p < 0.05
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Table 2 Clinical characteristics of gram-negative bacteraemia according to the results of follow-up blood culture (FUBC) and the
eradicability of the source of infection
Eradicable source of infection Non-eradicable source of infection
Positive FUBC
(n = 55)










Age, years (± SD) 69.18 (± 12.19) 70.15 (± 13.35) 0.610 70.15 (± 14.25) 67.98 (± 14.88) 0.254
Sex (M) 29 (52.7%) 222 (54.0%) 0.886 26 (39.4%) 346 (47.0%) 0.235
Body weight (kg)
Comorbidity
DM 19 (34.5%) 121 (29.4%) 0.531 25 (37.9%) 238 (32.3%) 0.358
Liver cirrhosis 6 (10.9%) 31 (7.5%) 0.422 4 (6.1%) 54 (7.3%) 1.000
ESRD on HD 4 (7.3%) 7 (1.7%) 0.031* 6 (9.1%) 18 (2.4%) 0.010*
ESRD on PD 0 (0.0%) 0 (0.0%) N.A. 2 (3.0%) 4 (.0.5%) 0.081
Rheumatic disease 1 (1.8%) 0 (0.0%) 0.119 2 (3.0%) 15 (2.0%) 0.644
Haematologic malignancy 4 (7.3%) 8 (2.0%) 0.042* 12 (18.2%) 109 (14.9%) 0.474
Solid malignancy 17 (30.9%) 149 (36.4%) 0.457 16 (24.2%) 176 (24.0%) 0.966
Solid organ transplantation 2 (3.6%) 9 (2.2%) 0.627 4 (6.1%) 19 (2.6%) 0.113
Bone marrow transplantation 2 (3.6%) 1 (0.2%) 0.038* 2 (3.0%) 22 (3.0%) 1.000
Intravascular device 75 (18.2%) 26 (47.3%) 0.000* 4 (6.1%) 19 (2.6%) 0.113
Neutropenia 1 (1.8%) 8 (2.0%) 1.000 11 (16.7%) 105 (14.3%) 0.608
High-dose steroid 1 (1.8%) 4 (1.0%) 0.468 4 (6.1%) 15 (2.0%) 0.063
Microorganism
Escherichia coli 22 (40.0%) 205 (49.9%) 0.197 36 (54.5%) 456 (62.0%) 0.291
Klebsiella pneumoniae 11 (20.0%) 91 (22.1%) 0.735 14 (21.2%) 133 (18.1%) 0.527
Pseudomonas aeruginosa 5 (9.1%) 19 (4.6%) 0.185 5 (7.6%) 33 (4.5%) 0.231
vAmpC-encoded Enterobacteriaceaea 7 (12.7%) 49 (11.9%) 1.000 4 (6.1%) 39 (5.3%) 0.774
Acinetobacter baumannii 1 (1.8%) 6 (1.5%) 0.587 2 (3.0%) 15 (2.0%) 0.644
ESBL-producing 21 (38.2%) 84 (20.4%) 0.003* 39 (59.1%) 169 (23.0%) 0.000*
Other gram-negative 9 (16.4%) 34 (8.3%) 0.052* 5 (7.6%) 59 (8.0%) 0.899
PBSI 5 (9.1%) 32 (7.8%) 0.789 1 (1.5%) 12 (1.6%) 1.000
Hospital onset 22 (40.0%) 66 (16.1%) 0.000* 19 (28.8%) 216 (29.3%) 1.000
Site of infection
Urinary genital tract 12 (21.8%) 80 (19.5%) 0.718 38 (57.6%) 372 (50.5%) 0.305
Liver abscess 2 (3.6%) 39 (9.5%) 0.205 0 (0.0%) 13 (1.8%) 0.615
Biliary infection 9 (16.4%) 218 (53.0%) 0.000* 1 (1.5%) 73 (9.9%) 0.024*
Intra-abdominal 5 (9.1%) 38 (9.2%) 1.000 6 (9.1%) 85 (11.5%) 0.687
Respiratory 1 (1.8%) 2 (0.5%) 0.315 7 (10.6%) 44 (6.0%) 0.180
SSTI 3 (5.5%) 4 (1.0%) 0.039* 2 (3.0%) 4 (0.5%) 0.081
Catheter-related 18 (32.1%) 22 (5.4%) 0.000* 0 (0.0%) 0 (0.0%) N.A.
Bone and joint infection 3 (5.5%) 2 (0.5%) 0.013* 1 (1.5%) 6 (0.8%) 0.453
Cardiovascular 2 (3.6%) 1 (0.2%) 0.038* 0 (0.0%) 0 (0.0%) N.A.
CNS infection 0 (0.0%) 0 (0.0%) N.A. 0 (0.0%) 2 (0.2%) 1.000
Primary bacteraemia 0 (0.0%) 0 (0.0%) N.A. 11 (16.7%) 131 (17.8%) 0.869
Inotropic requirement on the day of
FUBC
24 (5.8%) 10 (18.2%) 0.003* 9 (13.6%) 53 (7.2%) 0.061
Unfavourable treatment response 30 (55.6%) 130 (32.5%) 0.001* 31 (48.4%) 215 (30.0%) 0.002*
qSOFA score (± SD) on the day of FUBC 1.29 (± 1.12) 0.52 (± 0.76) 0.000* 0.88 (± 0.95) 0.56 (± 0.88) 0.005*
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antibiotics, and adequate source control. In cases where
the source of infection was non-eradicable, the independ-
ent risk factors were as follows: end-stage renal disease on
hemodialysis, unfavorable treatment responses, and the
administration of effective antibiotics. We assigned points
to the independent risk factors for positive FUBC, based
on the beta-coefficients from the logistic regression ana-
lysis (Table 3). In cases of eradicable and non-eradicable
sources of infection, the values of the area under the curve
of the receiver operating characteristic curve (AUC-ROC)
of each scoring model were 0.861 (95% confidence interval
(CI) 0.806–0.916) and 0.792 (95% CI, 0.724–0.861), re-
spectively (Table 3, Fig. 2). The sensitivities, specificities,
positive predictive values (PPVs), and negative predictive
values (NPVs) according to the cut-off values are listed in
Table 4.
When we applied a cut-off value of 0, the specificities
of the eradicable and non-eradicable sources of infection
were 95.6 and 95.5%, respectively. The NPVs of the pre-
dictive scoring models in the eradicable and non-
eradicable source infections were 92.6 and 95.0%,
respectively.
The percentage of positive FUBCs according to the
scores of eradicable and non-eradicable source of infec-
tion is shown in Fig. 3. The percentage of positive
FUBCs was less than 2% in cases with − 3 or − 2 points
of eradicable or non-eradicable sources of infection, but
40 and 70% had positive FUBCs in cases with 1 or 2
Table 2 Clinical characteristics of gram-negative bacteraemia according to the results of follow-up blood culture (FUBC) and the
eradicability of the source of infection (Continued)
Eradicable source of infection Non-eradicable source of infection
Positive FUBC
(n = 55)










SOFA score (± SD) on the day of FUBC 5.62 (± 4.48) 3.09 (± 2.93) 0.000* 3.79 (± 3.47) 2.90 (± 3.18) 0.036*
qSOFA score ≥ 2 on the day of FUBC 20 (36.4%) 45 (10.9%) 0.000* 16 (24.2%) 108 (14.7%) 0.039
Effective antibiotics before the day of
FUBC
34 (61.8%) 350 (85.2%) 0.000* 27 (40.9%) 639 (86.8%) 0.000*
Adequate source control before the day
of FUBC
13 (23.6%) 322 (78.3%) 0.000* N.A. N.A. N.A.
SD Standard deviation, N.A. Not available, M Male, DM Diabetes mellitus, ESRD End-stage renal disease, HD Haemodialysis, PD Peritoneal dialysis, ESBL Extended-
spectrum beta-lactamase, PBSI Polymicrobial bloodstream infection, SSTI Skin and soft tissue infection, CNS Central nervous system
aAmpC-encoded Enterobacteriaceae includes Serratia marcescens, Providencia stuartii, Proteus vulgaris, Citrobacter spp., Enterobacter spp., and Morganella morganii
*p < 0.05
Table 3 Independent risk factors and assigned scores used to build the predictive scoring model for positive follow-up blood
culture in gram-negative bacteraemia, according to eradicable and non-eradicable sources of infection
Eradicable source of infection
Beta-coefficient Odds ratio (95% CI) p-value Assigned score
ESBL-producing microorganism infection 1.001 2.720 (1.179–6.271) 0.019 + 1
CRBSI 1.374 3.95 (1.522–10.255) 0.005 + 1
Unfavourable treatment responsea 0.802 2.229 (1.262–3.937) 0.006 + 1
qSOFA score≥ 2 on the day of FUBC 0.864 2.371 (1.034–5.438) 0.041 + 1
Effective antibiotics administration before the day of FUBC −1.007 0.365 (0.164–0.814) 0.014 −1
Adequate source control before the day of FUBC −1.983 0.138 (0.064–0.294) 0.000 −2
Non-eradicable source of infection
ESRD on HD 1.406 4.081 (1.331–12.515) 0.014 + 1
Unfavourable treatment responsea 0.802 2.229 (1.262–3.937) 0.006 + 1
Effective antibiotics administration before the day of FUBC −2.015 0.133 (0.069–0.258) 0.000 −2
CI Confidence interval, ESBL Extended-spectrum beta-lactamase, CRBSI Catheter-related bloodstream infection, qSOFA Quick sequential organ failure assessment,
FUBC Follow-up blood culture, ESRD End-stage renal disease, HD Haemodialysis
aUnfavourable treatment response was defined as positivity for at least 2 variables among the presence of fever, aggravated leucocytosis, and no decrease of C-
reactive protein on the day of FUBC
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points of non-eradicable or eradicable sources of infec-
tion, respectively.
Discussion
Our study revealed that FUBCs were performed in most
of the patients with GNB, but less than 10% produced
positive results. In contrast to gram-positive bacteremia,
positive FUBC results were not common in GNB [1, 3].
In eradicable sources of infection, variables such as
ESBL-producing organisms, catheter-related bloodstream
infections (CRBSIs), unfavorable treatment responses, and
qSOFA scores of at least 2 were independent risk factors,
but when effective antibiotics were administered and there
was adequate source control the day before performing
FUBC, the probability of negative conversion of
bacteremia in FUBC increased significantly. When appro-
priate management (e.g., administration of effective antibi-
otics and source control) was performed, and there was a
clear clinical response (qSOFA score < 2), the score pre-
dicted by the model did not exceed the cut-off value (zero
points), and the probability of negative conversion in
FUBC was as high as 92.6%. In Staphylococcus aureus in-
fections, delays in the removal of eradicable sources of in-
fection, the initial administration of inappropriate
antibiotics, and delays in the delivery of appropriate anti-
biotics were important risk factors for persistent
bacteremia [10, 12]. Early source control (within 48 h) was
also important for eradicating bacteremia in both gram-
positive and gram-negative bacteremia [3]. Therefore, as
with S. aureus bacteremia, in cases of GNB with eradicable
sources of infection—regardless of the site of infection,
underlying diseases, or causative microorganisms—if there
is appropriate management and the clinical response is fa-
vorable, FUBC provides little benefit.
In cases in which the source of infection was non-
eradicable, hemodialysis and an unfavorable treatment
response were independent risk factors. However, if ef-
fective antibiotics were administered to the patient,
bacteremia was usually eliminated. If effective antibiotics
were administered—regardless of the underlying disease,
microorganism type, or treatment response—the score
did not exceed the cut off-value (zero points), and the
probability of negative conversion of bacteremia was
95.0%.
If FUBC was performed only in cases with more than
zero points of both eradicable and non-eradicable source
of infection, more than 90% of FUBCs could have been
avoided in our study population (Fig. 3). Even if the cut-
off value was more strictly set as − 1 to increase the
NPV, more than 70% of FUBCs could have been saved.
Therefore, performing FUBC to evaluate the response to
treatment can be avoided in most uncomplicated cases
of GNB. In GNB cases, FUBC could be applied select-
ively to patients with a high risk of positive FUBCs, un-
like in S. aureus bacteremia or candidemia.
The contamination rate of peripheral blood cultures in
our hospital is as low as 0.5%, and among the 1276 cases
of FUBC in our study, there were no suspected cases of
contamination. However, contamination rates in blood
cultures have been reported ranging from 0.9–7.9% [5].
In other studies related to FUBCs, contaminants were
identified in 2.0–3.9% of FUBCs [13, 14]. Therefore,
Fig. 2 a Receiver operating characteristic (ROC) analysis of the
predictive scoring model in cases with eradicable sources of
infection. The area under the curve (AUC) was 0.861 (95%
confidence interval (CI) 0.806–0.916). b ROC analysis of the predictive
scoring model in cases with non-eradicable sources of infection. The
AUC was 0.792 (95% CI, 0.724–0.861)
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universal FUBCs of all gram-negative bacteremia may
produce contamination, which could lead to increased
medical costs and prolonged hospital stays [5].
Recently, one study revealed that FUBC was a useful
diagnostic tool for differentiating septic thrombophlebitis
in gram-negative bacteremia of patients admitted to the
intensive care unit (ICU) for polytrauma [15]. If the pa-
tient had a high-risk of persistent GNB and risk factors for
deep vein thrombosis, such as the presence of a central
catheter, multiple traumas or admission to the ICU [16,
17], further diagnostic evaluation, such as CT angiography
and duplex sonography as well as FUBCs to differentiate
septic thrombophlebitis, could be considered.
Recent studies revealed that when FUBCs were per-
formed in cases of gram-negative bloodstream infection,
they were associated with improved clinical outcomes
[13, 14]. However, the proportion of FUBCs performed
was relatively low (17.6–68%) compared to our present
study (86.2%). In addition, the rates of positive FUBC
(20–38.5%) and all-cause mortality (10–13.7%) were
higher than in our study population (9.7% positive-
FUBC rate and 6.8% in-hospital mortality in the FUBC
group). This means that FUBCs were selectively per-
formed in severe GNB cases in these previous studies. It
cannot be concluded that FUBC improves the prognosis
in all GNB, especially in uncomplicated bacteremia. The
FUBC group in these studies had a trend of longer treat-
ment duration and hospital stays than the no-FUBC
group, and contaminants were identified in 2.0–3.9% of
FUBCs. If FUBC is conducted routinely in uncompli-
cated GNB, it may increase medical costs and cause vari-
ous side effects due to prolonged antibiotic treatment.
Therefore, the decision of conducting an FUBC should
be made carefully, and our predictive scoring model will
help with that decision. Appropriately conducted
FUBCs, according to the results of our predictive scoring
model, may improve clinical outcomes and reduce side
effects and medical costs.
Our study has some limitations. First, there may have
been bias towards the FUBC group, because the study
was conducted retrospectively. However, variables such
as hematologic malignancy, presence of an intravascular
device, and ESBL-producing microorganisms—which
were significantly more prevalent in the FUBC group
than in the no-FUBC group— were also significant risk
factors for positive FUBCs (Table 1). This means that
there was a higher probability of persistent bacteremia
in the FUBC group than in the no-FUBC group. The
NPVs of predictive scoring models in real-world cases of
GNB would be higher than those indicated in the
present study. Therefore, this selection bias did not alter
our conclusion. Second, we did not determine how
FUBC affects patient outcomes such as mortality, mor-
bidity, length of stay in hospital, or total cost of medical
care. Therefore, our findings alone will not be sufficient
to change routine practice. As discussed above, recent
studies have shown that FUBC was associated with im-
proved outcome of GNB [13, 14], but these results
couldn’t be applied to the uncomplicated GNB. Further
investigations such as a prospective randomized control
study should be conducted to reveal the exact clinical
impact of FUBC in GNB.
Conclusions
In this study, although FUBC was commonly used in
cases of GNB, there were few positive results (< 10% of
cases). We expect that the application of our simple pre-
dictive scoring model will reduce the need for perform-
ing unnecessary FUBC in uncomplicated cases of GNB.
Table 4 Receiver operating characteristics and predictability of scoring models for positive follow-up blood culture in gram-negative
bacteraemia, according to the various cut-off values
AUC (95% CI) Cut-off Sensitivity Specificity PPV NPV
Eradicable source of infectiona 0.861 (0.806–0.916) −2 88.5% 67.0% 27.7% 97.6%
−1 76.9% 82.1% 38.1% 96.1%
0 46.2% 95.6% 60.0% 92.6%
1 17.3% 99.3% 75% 90.63%
2 3.8% 100% 100% 87.9%
Non-eradicable source of infection 0.792 (0.724–0.861) −2 83.9% 58.4% 14.4% 97.6%
−1 58.9% 86.9% 27.3% 96.2%
0 39.3% 95.5% 42.3% 95.0%
1 3.6% 100.0% 100.0% 92.5%
AUC Area under the curve, CI Confidence interval, PPV Positive predictive value, NPV Negative predictive value
aGram-negative bacteraemia in which the primary source of infection could be removed, e.g. removal of a central venous catheter or other endovascular device,
drainage of a dilated bile duct or hydronephrosis, surgical debridement of skin and soft tissue infection or osteomyelitis, drainage or removal of an intra-
abdominal abscess, or drainage of empyema or a lung abscess
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Fig. 3 a The percentage of positive follow-up blood cultures according to the scores of eradicable and b non-eradicable source of infection
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